Omada Health Earnings Call Signals Strong Growth Ahead
Omada Health (OMDA) reported Q3 revenue of $91M, up 34% YoY, with GAAP net income of $7M vs. a loss last year. Adjusted EBITDA rose to $12M. Management raised 2026 revenue guidance to $344M-$346M and adjusted EBITDA to $32M-$34M, citing strong demand for diabetes and hypertension programs. The company expects Q4 seasonality and GLP-1 coverage uncertainty.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise suggest near‑term upside, but execution risk remains.
Market read
First‑report earnings and guidance lift for a listed digital‑health firm, offering a clear trading catalyst.
What to watch
Potential headwinds from employer GLP‑1 coverage decisions and near‑term enrollment moderation.
Background
Omada Health reported Q3 results with record revenue, profit and raised guidance, while noting seasonal Q4 slowdown and GLP‑1 coverage uncertainty.
Ticker impact
Q3 earnings released with record revenue and raised 2026 guidance to $344‑$346M.
likely upward as investors price in stronger growth outlook
Revenue beat, GAAP profit and higher guidance signal improved fundamentals, prompting buying interest.
Market effects
Positive signal for digital health and chronic‑care management sector.
U.S. market may see modest lift in health‑tech stocks.
Limited to investors focused on U.S. digital‑health equities.
Counterpoint
Higher guidance may be offset by uncertainty around GLP‑1 coverage and Q4 seasonality.
Key entities
- companyOmada Health, Inc.
Digital health platform delivering chronic‑care programs.
- personWei‑Li Shao
Incoming CEO effective Jan 1 2027.
